Thousands of breast cancer patients in the UK could potentially be spared the harsh side effects of chemotherapy, thanks to findings from a new international trial. The study suggests that a novel DNA test can accurately identify individuals with certain types of early-stage breast cancer who would not benefit from the treatment, allowing them to safely avoid it.
Chemotherapy is a cornerstone of cancer treatment, but it comes with significant adverse effects, including fatigue, nausea, hair loss, and increased risk of infection. For many patients, these side effects severely impact their quality of life. The new DNA test works by analysing the genetic make-up of a patient's tumour, providing a clearer picture of its aggressiveness and its likely response to different treatments. This personalised approach aims to tailor therapy more precisely, ensuring only those who truly need chemotherapy receive it.
Currently, treatment decisions for breast cancer are based on various factors, including tumour size, grade, and lymph node involvement. While these methods are effective, there remains a proportion of patients who undergo chemotherapy without a clear survival benefit. This new diagnostic tool could refine this process, helping clinicians make more informed decisions and reduce overtreatment.
The implications for the National Health Service (NHS) are substantial. Reducing the number of patients undergoing chemotherapy would free up valuable resources, including oncology staff time, chemotherapy suites, and associated support services. Furthermore, it could lead to a reduction in hospital admissions for managing chemotherapy-related complications, easing pressure on an already stretched healthcare system.
While the study's findings are promising, it is important to note that this DNA test is not yet routinely available within the NHS. Further validation, regulatory approval, and health technology assessment by organisations such as the National Institute for Health and Care Excellence (NICE) would be required before it could be widely adopted. Patients should always discuss their treatment options with their oncology team. For medical concerns, individuals should consult their GP or call NHS 111.